Penumbra (PEN) Starts The FORWARD Study, Is The Stock Already Expensive?

FORWARD stroke study puts Penumbra (PEN) thrombectomy platform in focus

Penumbra (PEN) has kicked off the FORWARD study, an international, real world trial tracking safety and efficacy of its RED reperfusion catheter portfolio, including the newly cleared THUNDERBOLT thrombectomy platform.

See our latest analysis for Penumbra.

Penumbra’s US$318.32 share price has been relatively steady in recent weeks, with modest short term moves. The 1 year total shareholder return of 38.17% points to stronger longer term momentum as investors weigh product updates like FORWARD.

If this kind of medical technology story interests you, it may be worth scanning other healthcare AI opportunities through our curated 39 healthcare AI stocks

With Penumbra shares steady around US$318.32 after the FORWARD and THUNDERBOLT updates, the key question is whether to accept today’s price or hold out for a cheaper entry as the valuation work starts next.

Most Popular Narrative: 12.4% Undervalued

Penumbra's most followed narrative pegs fair value around $363 per share, comfortably above the last close at $318.32. This sets up a valuation story tightly linked to clinical data and earnings projections.

The soon to be released STORM PE randomized trial is poised to provide Level 1 evidence comparing Penumbra's thrombectomy technology to standard anticoagulation for pulmonary embolism. A positive outcome could expand guideline adoption, significantly accelerate procedure volumes, and drive substantial revenue growth by rapidly increasing penetration in a very underpenetrated, large market.

Read the complete narrative.

Want to see what sits behind that fair value gap? The narrative leans on compounding revenue, rising margins and a rich earnings multiple that assumes meaningful scale.

Result: Fair Value of $363.36 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this Penumbra narrative could be knocked off course if trial data disappoints, or if increasing competition and regulatory scrutiny pressure pricing and margins.

Find out about the key risks to this Penumbra narrative.

Another View: Penumbra looks expensive on earnings multiples

The narrative-driven fair value of around $363 for Penumbra sits awkwardly next to its current P/E of 73.2x, which is much higher than the US Medical Equipment industry at 27.2x, peers at 26.4x and a fair ratio of 27.8x. This raises the question of whether the market is already pricing in a lot of good news.

On this view, valuation risk is clear, as any disappointment relative to expectations could see sentiment shift toward that lower fair ratio level. This in turn raises the question of how much upside is left if growth and margins land closer to industry norms.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Given the mixed sentiment around Penumbra, it makes sense to move quickly, review the data for yourself, and weigh the potential rewards highlighted in the 2 key rewards

Looking for more investment ideas beyond Penumbra?

If Penumbra has sharpened your focus on quality opportunities, do not stop here. Use the Simply Wall Street Screener to line up your next watchlist candidates.

• Target potential mispricings by scanning companies that look attractively priced on fundamentals through our curated 47 high quality undervalued stocks.
• Strengthen your income stream by reviewing companies with robust payouts using the carefully filtered 8 dividend fortresses.
• Prioritise resilience by checking stocks that score well on financial stability and fundamentals via the focused solid balance sheet and fundamentals stocks screener (47 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com